Skip to main content
Tony (Vanho) Ho, MD, Oncology, Portland, OR

Tony V (Vanho) Ho MD

Hematologic Oncology


Physician

Join to View Full Profile
  • 265 N BroadwayPortland, OR 97227

  • Phone+1 503-280-1223

  • Fax+1 503-528-5252

Are you Dr. Ho?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Tony (Vanho) Ho, MD is an oncologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon and Washington.

Education & Training

  • University of Utah Health
    University of Utah HealthFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Legacy Health/Emanuel Medical Center
    Legacy Health/Emanuel Medical CenterResidency, Internal Medicine, 1996 - 1999
  • University of Utah School of Medicine
    University of Utah School of MedicineClass of 1996

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2002 - 2025
  • WA State Medical License
    WA State Medical License 2002 - 2025
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Press Mentions

  • iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of Directors
    iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of DirectorsMay 3rd, 2021
  • iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of Directors
    iTeos Appoints Tony Ho M.D. And Robert Iannone M.D., M.S.C.E., Two Highly Accomplished R&D Executives to Its Board of DirectorsMay 3rd, 2021
  • CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel in Vivo Delivery Technologies
    CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel in Vivo Delivery TechnologiesJanuary 22nd, 2019